| __timestamp | Dr. Reddy's Laboratories Limited | Incyte Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 56369000000 | 3004000 |
| Thursday, January 1, 2015 | 62786000000 | 26972000 |
| Friday, January 1, 2016 | 62427000000 | 58187000 |
| Sunday, January 1, 2017 | 62453000000 | 79479000 |
| Monday, January 1, 2018 | 65724000000 | 94123000 |
| Tuesday, January 1, 2019 | 70421000000 | 114249000 |
| Wednesday, January 1, 2020 | 80591000000 | 131328000 |
| Friday, January 1, 2021 | 86645000000 | 150991000 |
| Saturday, January 1, 2022 | 100551000000 | 206997000 |
| Sunday, January 1, 2023 | 42907000000 | 255000000 |
| Monday, January 1, 2024 | 115557000000 | 312068000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. This chart highlights the cost of revenue trends for Incyte Corporation and Dr. Reddy's Laboratories Limited from 2014 to 2023. Dr. Reddy's Laboratories, a global pharmaceutical giant, consistently shows a robust cost of revenue, peaking at approximately 115% of its 2014 value by 2024. In contrast, Incyte Corporation, a biopharmaceutical innovator, exhibits a more modest growth, with its cost of revenue increasing by over 8,000% from 2014 to 2023. This stark contrast underscores the differing scales and operational strategies of these companies. Notably, Dr. Reddy's experienced a significant dip in 2023, while Incyte's costs continued to rise, reflecting potential strategic shifts or market conditions. Missing data for 2024 suggests ongoing developments. This analysis offers a window into the financial strategies shaping the pharmaceutical landscape.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Incyte Corporation
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost Insights: Breaking Down Incyte Corporation and ACADIA Pharmaceuticals Inc.'s Expenses
Incyte Corporation vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Dr. Reddy's Laboratories Limited and BioMarin Pharmaceutical Inc.
Cost of Revenue Trends: Dr. Reddy's Laboratories Limited vs Sarepta Therapeutics, Inc.
Cost of Revenue Comparison: Dr. Reddy's Laboratories Limited vs Lantheus Holdings, Inc.
Comparing Cost of Revenue Efficiency: Dr. Reddy's Laboratories Limited vs Grifols, S.A.
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Ligand Pharmaceuticals Incorporated: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Geron Corporation: Efficiency in Cost of Revenue Explored